From the Department Otolaryngology-Head and Neck Surgery, University of California at San Francisco, San Francisco, CA.
Cancer J. 2023;29(1):38-46. doi: 10.1097/PPO.0000000000000639.
Cancer is defined by the presence of uncontrollable cell growth, whereby improper proliferative signaling has overcome regulation by cellular mechanisms. Transcription factors are uniquely situated at the helm of signaling, merging extracellular stimuli with intracellular responses. Therefore, this class of proteins plays a pivotal role in coordinating the correct gene expression levels for maintaining normal cellular functions. Dysregulation of transcription factor activity unsurprisingly drives tumorigenesis and oncogenic transformation. Although this imparts considerable therapeutic potential to targeting transcription factors, their lack of enzymatic activity renders intervention challenging and has contributed to a sense that transcription factors are "undruggable." Yet, enduring efforts to elucidate strategies for targeting transcription factors as well as a deeper understanding of their interactions with binding partners have led to advancements that are emerging to counter this narrative. Here, we highlight some of these approaches, focusing primarily on therapeutics that have advanced to the clinic.
癌症的定义是存在不可控的细胞生长,其中不当的增殖信号已经克服了细胞机制的调节。转录因子位于信号的掌舵位置,将细胞外刺激与细胞内反应结合在一起。因此,这类蛋白质在协调维持正常细胞功能的正确基因表达水平方面起着关键作用。转录因子活性的失调无疑会导致肿瘤发生和致癌转化。尽管这为靶向转录因子提供了相当大的治疗潜力,但它们缺乏酶活性使得干预具有挑战性,并导致人们认为转录因子是“不可成药的”。然而,为阐明靶向转录因子的策略以及深入了解它们与结合伙伴的相互作用而进行的不懈努力,已经取得了一些进展,这些进展正在出现,以扭转这种局面。在这里,我们重点介绍其中的一些方法,主要关注已经进入临床的治疗方法。